Hansoh Pharma Presents Phase II Clinical Data of HS-20094, a GLP-1R/GIPR Dual Agonist, at the 2024 American Diabetes Association Scientific Sessions

From June 21 to 24, the 2024 American Diabetes Association (ADA) Annual Meeting was held in Orlando, USA. The Phase II clinical research data of Hansoh Pharma's HS-20094 (GLP-1R/GIPR dual-target agonist) was presented at the conference in the form of a poster and an electronic poster with live Q&A.

The ADA annual meeting is the largest and most prestigious diabetes academic conference in the world, attracting nearly 16,000 participants from around the globe each year, including clinicians, nurses, researchers, and more. The conference provides attendees with the opportunity to interact with diabetes experts and share insights, offering researchers and healthcare professionals access to the latest significant advances in diabetes research, treatment, and care.

Latest Report: In 2021, approximately 537 million adults (aged 20-79) worldwide had diabetes (about 1 in 10 people were diabetic); this number is expected to rise to 643 million by 2030 and to 783 million by 2045. During this period, the global population is estimated to grow by 20%, while the number of people with diabetes is projected to increase by 46%. The prevalence of type 2 diabetes in China shows an increasing trend year by year. From 2015 to 2017, the prevalence of diabetes in China reached 11.2%, with over 90% being cases of type 2 diabetes.

HS-20094 is a dual agonist of glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor independently developed by Hansoh Pharma. By selectively activating GLP-1 receptor and GIP receptor, it promotes insulin secretion, delays gastric emptying, and suppresses appetite to reduce food intake, thereby generating biological effects such as blood sugar control, weight loss, and metabolic improvement. Its administration method is once weekly subcutaneous injection.

The phase II study results of HS-20094 published this time show that HS-20094 has good safety and tolerability characteristics in subjects with type 2 diabetes, and demonstrates excellent glucose-lowering and weight-reducing efficacy.

Research data shows that in patients with diabetes, HS-20094 demonstrated good safety and tolerability within the 5~15mg dose range. It significantly outperformed the placebo group in both glucose-lowering and weight-reducing effects. Moreover, compared with semaglutide, HS-20094 at a 15mg dose exhibited significant advantages in both glucose-lowering and weight-reducing efficacy.

Currently, Hansoh Pharma has initiated and is accelerating the advancement of later-stage research on HS-20094 for patients with type 2 diabetes and those who are overweight or obese in China, in the hope of providing more options for the aforementioned patient groups.